Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.

Amicus Therapeutics (FOLD) could be a solid choice for investors given the company's remarkably improving earnings outlook.

Learn more about whether ADMA Biologics, Inc. or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

Assetmark Inc. Scales Down Stake in Amicus Therapeutics Amid Strategic Portfolio Rebalancing | S&P 500 Futures Tracker ...

Highlights,XTX Topco Ltd significantly increased its position in Amicus Therapeutics during the first quarter,Shares of ...

Amicus Therapeutics Inc (FOLD) reports its 17th consecutive quarter of double-digit revenue growth, while navigating increased operating expenses and ongoing litigation challenges.

As you might know, Amicus Therapeutics, Inc. ( NASDAQ:FOLD ) just kicked off its latest second-quarter results ...

Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out ...

Q2 2025 Earnings Call Transcript July 31, 2025 Amicus Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Discover Amicus Therapeutics' Q2 2025 growth insights, double-digit revenue gains, pipeline milestones, and confidence in $1B sales targets for ...

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is one of the best strong buy stocks to buy under $10. In a report released on July ...

Second Quarter 2025 Financial Highlights: Total revenues for the second quarter 2025 were $154.7 million, reflecting strong ...